Aldeyra Therapeutics (ALDX) Current Assets (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Current Assets came in at $66.3 million in Q1 2026, down 28.53% YoY from $92.7 million in Q1 2025, and down 7.68% on a QoQ basis from $71.8 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Current Assets (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Current Assets data on file, last reported at $66.3 million in Q1 2026.
- Quarterly Current Assets fell 28.53% year-over-year to $66.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.3 million (down 28.53% YoY) and the FY2025 annual result came in at $71.8 million, down 31.03% from the prior year.
- Current Assets retreated to $66.3 million in Q1 2026, from $71.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $222.4 million in Q1 2022 to a low of $66.3 million in Q1 2026.
- A 5-year average of $134.8 million and a median of $140.8 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 51.19% — and 2025, when it slumped 34.16%.
- Tracing ALDX's Current Assets over 5 years: stood at $181.0 million in 2022, then decreased by 18.35% to $147.8 million in 2023, then declined by 29.59% to $104.1 million in 2024, then slumped by 31.03% to $71.8 million in 2025, then fell by 7.68% to $66.3 million in 2026.
- The last three Current Assets figures came in at $66.3 million (Q1 2026), $71.8 million (Q4 2025), and $77.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | 47.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.38 Mn |
| Mar 31, 2026 | 66.27 Mn |
| Dec 31, 2025 | 71.78 Mn |
| Sep 30, 2025 | 77.46 Mn |
| Jun 30, 2025 | 84.56 Mn |
| Mar 31, 2025 | 92.73 Mn |
| Dec 31, 2024 | 104.07 Mn |
| Sep 30, 2024 | 116.72 Mn |
| Jun 30, 2024 | 125.65 Mn |
| Mar 31, 2024 | 140.85 Mn |
| Dec 31, 2023 | 147.81 Mn |
| Sep 30, 2023 | 147.21 Mn |
| Jun 30, 2023 | 155.48 Mn |
| Mar 31, 2023 | 168.02 Mn |
| Dec 31, 2022 | 181.02 Mn |
| Sep 30, 2022 | 189.48 Mn |
| Jun 30, 2022 | 200.74 Mn |
| Mar 31, 2022 | 222.36 Mn |
| Dec 31, 2021 | 232.75 Mn |
| Sep 30, 2021 | 246.77 Mn |